Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.

Autor: Li MSC; Department of Clinical Oncology, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.; State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong., Lee KWC; Department of Clinical Oncology, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong., Mok KKS; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Loong HHF; Department of Clinical Oncology, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong., Lam KC; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Mok FST; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Chan LL; Department of Clinical Oncology, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong., Lau YM; Department of Oncology/Haematology, St Vincent's Hospital, Sydney, Australia., Chan KP; Department of Medicine, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong., Ng JTY; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Wong WKY; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Lam BHW; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Chen ACC; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Lee MMP; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Chen OH; Department of Clinical Oncology, Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong., Mok TSK; Department of Clinical Oncology, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.; State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Sha Tin, New Territories, Hong Kong.

Publikováno v: JTO clinical and research reports [JTO Clin Res Rep] 2024 Feb 10; Vol. 5 (4), pp. 100648. Date of Electronic Publication: 2024 Feb 10 (Print Publication: 2024).